New shingles vaccine 'superior' but comes with a sting

PBAC to consider listing Shingrix on National Immunisation Program for herpes zoster in over-60s

The newest shingles vaccine, Shingrix, has a nearly twofold increase in injection site reactions compared with the live attenuated vaccine Zostavax, according to a systematic review.


It’s the first time the two vaccines have been compared, albeit indirectly, for safety and efficacy, say the Canadian authors behind the analysis.

The study showed that compared with Zostavax (MSD), GSK’s adjuvant recombinant subunit vaccine reduced confirmed cases of shingles by 85% and suspected cases by 63% in adults aged 50 years or older.